Form 4: Lyell Immunopharma CEO Executes Tax-Related Stock Sale

CEO Lynn Seely sold 388 shares of Lyell Immunopharma to satisfy tax withholding obligations related to vested restricted stock units.

Summary

• Reporting person Lynn Seely, President and CEO of Lyell Immunopharma, Inc., sold 388 shares of common stock.
• The transaction occurred on May 11, 2026.
• The shares were sold at a weighted average price of $18.91 per share, with a price range between $18.91 and $19.15.
• Following the transaction, the reporting person maintains beneficial ownership of 73,878 shares.
• The sale was executed automatically to cover tax withholding obligations resulting from the settlement of vested restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a change in management sentiment.

Positives

• The transaction was a mandatory, non-discretionary sale to cover tax liabilities, rather than a discretionary divestment of shares.

Negatives

• Reduction in the CEO's direct equity stake in the company.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice for executives in the biotechnology sector to manage tax liabilities associated with equity-based compensation vesting.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity management.
• The use of automatic sell-to-cover mechanisms is consistent with industry norms for publicly traded biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and small in volume.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Insider Trading, Form 4, Biotech, Executive Compensation